The goal of BioLabShare, LLC is to create a foundation for the development and expansion of startup and emerging biophrama/biotechnology/life sciences by supporting quality and affordable biolab share and coworker office space that will provide support of the entrepreneurial spirit and access to equity investment.

I founded the company to address an unmet need in the area of drug development. As CSO, it is my role to design and guide the company's lead products through preclinical and clinical trials. In addition, I direct the company's research focus and scientific collaborations and partnerships. (www.pepvax.co)

My capacity at BSU will be to partner with the faculty of their science department in the development of commercialized bioresearch products for either cancer and/or infectious disease.

In 2017, Dr. Anton Dormer and Dr. Yonnette Semple-Dormer decided to make a name change to the nonprofit to reflect our commitment to creating bioresearch and science education opportunities for diverse populations. The name change from DOBI to Semple-Dormer BioInstitute, Inc. reflects that commitment. SDBI is a 501(c)3 non-profit biotechnology and science education company. Its focus is to guide the development of our protien carrier as a vaccine tool. At present, I am in charge of drug design and development and product development guidance through pre-clinical trails. I am also the primary person for the company in developing new leads for funding and partnership acquisition. The company offers a course in called In Silico Peptide Vaccine Design worldwide which was created teach student how to design peptide vaccine using bioinformatics tools. In addition, the company is focused in working with institutions around the globe in developing and upgrading the research capacity using bioinformatics. The nonprofit ultimate goal is to have its own building where cutting edge immunotherapy and DNA drug deliver systems can be researched and individuals of diverse backgrounds can learn drug discovery techniques.

Immage Biotherapeutics Corp. (OTC: IMMG) has been founded on the foundational understanding that many cancers can be treated via the harnessing the power of the human immune system. The pipeline of the company consists of a DNA viral vaccine construct that is target to tumors that expresses the Melanoma antigen family – A (MAGE-A) antigen.The company has a pipeline of therapeutics that has a high success probability because our treatment targets patient population medical needs are not being met at this time. Our leading pipeline is a universal vaccine that can be used for any tumor that expresses tumor antigen MAGE-A. This treatment can be targeted to cancers that have a high expression of the MAGE-A antigen including, breast, colon, pancreas, glioblastoma, and esophageal squamous cell carcinomas, for example. The company expects to focus on developing the treatment for triple negative breast cancer.

I am also the program coordinator for the Bioinformatics Interdisciplinary Program (BIP) at Washington Adventist University (WAU). The BIP consist of a minor in Applied Bioinformatics. The goal of the program is to add value to the science degree offerings of WAU and includes research and internship possibilities. I also teach several course, such as, Animal Diversity, Bioinformatics, Cell Biology, and In Silico Peptide Vaccine Design.

In this position I taught several biology courses such as General Biology and Anatomy and Physiology. Other courses that I taught while there was Medical Terminology. I also supported student research in the area of plant genomics and bioinformatics.